TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24853566

Group type: EXPERIMENTAL
Intervention: Text messages for medication reminders and education
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Text messages for education
Number of subjects: 90

Group type: COMPARATOR
Intervention: No text messages
Number of subjects: 90
Study: 24229729

Group type: EXPERIMENTAL
Intervention: eCases level 2
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: eCases level 2+
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: eTextbook level 2
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: eTextbook level 2+
Number of subjects: 120
Study: 21636012

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation of hop rho iso-alpha acids (200 mg), berberine sulfate trihydrate (100 mg), vitamin D₃ (500 IU), and vitamin K₁ (500 μg) twice daily
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 51
Study: 17651103

Group type: EXPERIMENTAL
Intervention: Low-dose dobutamine infusion (10 microg/kg/min)
Number of subjects: 70
Study: 16218198

Group type: EXPERIMENTAL
Intervention: Blink Reflex (BR)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Healthy group (control)
Number of subjects: 188
Study: 12045515

Group type: EXPERIMENTAL
Intervention: Postoperative scoliosis patients (after spine fusion)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Preoperative scoliosis patients
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normal subjects (control)
Number of subjects: 19
Study: 10471456

Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg daily)
Number of subjects: 1663

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1663
Study: 7598921

Group type: EXPERIMENTAL
Intervention: LMA inserted with cuff partially inflated
Number of subjects: 350

Group type: COMPARATOR
Intervention: LMA inserted with cuff fully deflated
Number of subjects: 350
Study: 2221164

Group type: EXPERIMENTAL
Intervention: Desipramine hydrochloride
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 67348

Group type: EXPERIMENTAL
Intervention: Day-case surgery (discharge after 8 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long-stay surgery (discharge on 5th or 6th day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Day-case surgery
Number of subjects: 0
Study: 30409941

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: 2% lidocaine hydrochloride with 1:200,000 adrenaline
Number of subjects: 20
Study: 27322670

Group type: EXPERIMENTAL
Intervention: Explicit social support
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Implicit social support
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 58
Study: 24843963

Group type: EXPERIMENTAL
Intervention: Acupuncture-moxibustion therapy
Number of subjects: 128

Group type: COMPARATOR
Intervention: Qianliekang tablets (Control)
Number of subjects: 128
Study: 22619605

Group type: EXPERIMENTAL
Intervention: Modified Gufoni's manoeuvre
Number of subjects: 87

Group type: COMPARATOR
Intervention: Gufoni's manoeuvre
Number of subjects: 87
Study: 20815194

Group type: EXPERIMENTAL
Intervention: Nasal airflow (Flow Wizard, DiagnoselT, Australia)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Nasal airflow (Flow Wizard, DiagnoselT, Australia) + Oximetry (Radical Set, Masimo, USA)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Oximetry (Radical Set, Masimo, USA)
Number of subjects: 105
Study: 18535115

Group type: EXPERIMENTAL
Intervention: Etanercept plus methotrexate
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 682
Study: 15673879

Group type: EXPERIMENTAL
Intervention: Propofol (mild sedation at 0.5 mug/mL)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Propofol (moderate sedation at 1.0 mug/mL)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 18
Study: 12669746

Group type: EXPERIMENTAL
Intervention: Preattentive auditory streaming
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention-dependent auditory streaming
Number of subjects: 0
Study: 11103752

Group type: EXPERIMENTAL
Intervention: Rifampin (600 mg once daily for 5 days)
Number of subjects: 9
Study: 8873392

Group type: EXPERIMENTAL
Intervention: IRIV‐HAV
Number of subjects: 301

Group type: COMPARATOR
Intervention: Al‐HAV
Number of subjects: 301
Study: 1556366

Group type: EXPERIMENTAL
Intervention: Management system of restraint release using colored pads corresponding to specific hours.
Number of subjects: 63

Group type: COMPARATOR
Intervention: Baseline monitoring (no intervention).
Number of subjects: 63

Group type: COMPARATOR
Intervention: Post-intervention monitoring (no intervention).
Number of subjects: 63
Study: 3888857

Group type: EXPERIMENTAL
Intervention: Oxyfedrine (8-24 mg three times a day)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Propranolol (40-80 mg three times a day)
Number of subjects: 14
Study: 31723854

Group type: EXPERIMENTAL
Intervention: High flow nasal cannula (HFNC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nasal cannula (NC)
Number of subjects: 24
Study: 26062785

Group type: COMPARATOR
Intervention: 10 mg memantine
Number of subjects: 84

Group type: COMPARATOR
Intervention: 20 mg memantine
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 24940052

Group type: EXPERIMENTAL
Intervention: Calcium fructoborate (CFB) 110 mg twice per day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 22908089

Group type: EXPERIMENTAL
Intervention: Crest 1100
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Crest 500
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Pooneh 500
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Pooneh without fluoride
Number of subjects: 56
Study: 20606475

Group type: EXPERIMENTAL
Intervention: True acupressure (applied for 4 weeks, three times a week)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: True acupressure
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo acupressure (applied for 4 weeks, three times a week)
Number of subjects: 28
Study: 18070439

Group type: EXPERIMENTAL
Intervention: Low dose midazolam sedation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study: 15681985

Group type: EXPERIMENTAL
Intervention: Emotional and educational intervention focusing on recurrence of breast cancer, 4 weeks duration, weekly meetings
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 78
Study: 11951158

Group type: EXPERIMENTAL
Intervention: High-intensity training program on cycle ergometers (5 training units weekly at 40 minutes each for a minimum of 22 training units during 4 weeks)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 125
Study: 10588463

Group type: EXPERIMENTAL
Intervention: 1.25 mg of warfarin daily in combination with 75 mg of aspirin
Number of subjects: 97

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 97
Study: 8921777

Group type: EXPERIMENTAL
Intervention: Baseline total cholesterol (6.11 mmol/L), non-HDL cholesterol (4.72 mmol/L), LDL cholesterol (3.98 mmol/L)
Number of subjects: 4736

Group type: EXPERIMENTAL
Intervention: Baseline HDL cholesterol (1.39 mmol/L) and triglycerides (1.62 mmol/L for fasting participants)
Number of subjects: 4736

Group type: EXPERIMENTAL
Intervention: Fasting participants with triglycerides < 4.52 mmol/L
Number of subjects: 4736
Study: 1495150

Group type: EXPERIMENTAL
Intervention: Silver sulfadiazine 1% cream
Number of subjects: 86

Group type: COMPARATOR
Intervention: Biologically active tripeptide copper complex 0.4% cream
Number of subjects: 86

Group type: COMPARATOR
Intervention: Inert vehicle placebo
Number of subjects: 86
Study: 6386793

Group type: EXPERIMENTAL
Intervention: Dothiepin
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 30844053

Group type: EXPERIMENTAL
Intervention: Isomaltulose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sucrose plus acarbose
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 20
Study: 30320654

Group type: EXPERIMENTAL
Intervention: Nurse's intentional presence (4 sessions of 30-45 minutes each)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no intentional presence)
Number of subjects: 80
Study: 27060679

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: 1000 IU Vitamin D
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: 2000 IU Vitamin D
Number of subjects: 260
Study: 23184565

Group type: EXPERIMENTAL
Intervention: Baseline albuminuria (defined as an albumin‐to‐creatinine ratio≥30 mg/g)
Number of subjects: 4597

Group type: EXPERIMENTAL
Intervention: Macroalbuminuria
Number of subjects: 4597

Group type: EXPERIMENTAL
Intervention: Microalbuminuria
Number of subjects: 4597

Group type: EXPERIMENTAL
Intervention: Rapid loss of estimated GFR over the first 2 years of follow‐up
Number of subjects: 4597
Study: 21619748

Group type: EXPERIMENTAL
Intervention: Rapid antigen detection testing (RADT)
Number of subjects: 543

Group type: COMPARATOR
Intervention: Control group (usual care, without RADT)
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: RADT
Number of subjects: 543
Study: 19502288

Group type: EXPERIMENTAL
Intervention: Cerebral State Monitor (CSM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bispectral Index (BIS)
Number of subjects: 40
Study: 16763388

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Growth hormone provocation test
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Overnight frequent GH sampling
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Thyroid function tests
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Lipid profile testing
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Immunoglobulin testing
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: D-xylose absorption test and fecal fat measurement
Number of subjects: 11
Study: 15567207

Group type: EXPERIMENTAL
Intervention: Patients with co-occurring significant general medical conditions (GMCs)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Patients without GMCs
Number of subjects: 1500
Study: 11513909

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (200 or 400 mg depending on bodyweight)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 9286179

Group type: EXPERIMENTAL
Intervention: Methadone plus counseling (low level of support)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Methadone plus more intensive counseling (intermediate level of support)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Methadone plus enhanced counseling, medical, and psychosocial services (high level of support)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Methadone plus enhanced services (high-intensity, high-cost)
Number of subjects: 100
Study: 8290452

Group type: EXPERIMENTAL
Intervention: HAD Hand Wash (povidone-iodine alcoholic disinfectant solution)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Benzalkonium chloride alcoholic lotion
Number of subjects: 0
Study: 2949585

Group type: EXPERIMENTAL
Intervention: PN 200‐110 (isradipine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 0

Group type: COMPARATOR
Intervention: HCTZ
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PN 200‐110 (isradipine) + HCTZ
Number of subjects: 0
Study: 29624463

Group type: EXPERIMENTAL
Intervention: Adjuvant androgen deprivation therapy (ADT) with bicalutamide and goserelin for 2 years
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: Adjuvant androgen deprivation therapy (ADT) plus mitoxantrone and prednisone (MP)
Number of subjects: 961

Group type: COMPARATOR
Intervention: Adjuvant androgen deprivation therapy (ADT)
Number of subjects: 961
Study: 27342046

Group type: EXPERIMENTAL
Intervention: Oral Lactobacillus rhamnosus GR‐1 and L reuteri RC‐14 (109 colony‐forming units) administered for 8 weeks
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo administered for 8 weeks
Number of subjects: 320
Study: 23963460

Group type: EXPERIMENTAL
Intervention: Iron and ascorbic acid
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Number of subjects: 153

Group type: COMPARATOR
Intervention: Plain water
Number of subjects: 153
Study: 22264372

Group type: EXPERIMENTAL
Intervention: Early tracheostomy within the first three days from intubation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Prolonged intubation (and possibly late tracheostomy) between days 7 and 14 from intubation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Early tracheostomy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Prolonged intubation
Number of subjects: 30
Study: 20828987

Group type: EXPERIMENTAL
Intervention: Moral Theme Inventory (MTI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Socio-Moral Reflection Measure--Short Form (SRM--SF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moral Theme Inventory (MTI) and Socio-Moral Reflection Measure--Short Form (SRM--SF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of moral reasoning abilities
Number of subjects: 0
Study: 18837655

Group type: EXPERIMENTAL
Intervention: Photoselective vaporization of the prostate (PVP)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Open prostatectomy (OP)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Both groups (PVP and OP)
Number of subjects: 125
Study: 19432501

Group type: EXPERIMENTAL
Intervention: Olmesartan 40 mg plus Amlodipine 5 mg or 10 mg
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Olmesartan 40 mg plus Amlodipine 10 mg
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Olmesartan 40 mg plus Amlodipine 10 mg (separate factorial study)
Number of subjects: 578
Study: 15784799

Group type: EXPERIMENTAL
Intervention: Placebo treatment (single dose of vitamin E)
Number of subjects: 54

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 54
Study: 12436823

Group type: EXPERIMENTAL
Intervention: Local delivery of antimicrobial agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systemic antimicrobial agents
Number of subjects: 0
Study: 9745150

Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution (LRS) 1,500 ml at 25 ml/min
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) 500 ml at 25 ml/min
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group (no infusion)
Number of subjects: 119
Study: 7821060

Group type: EXPERIMENTAL
Intervention: Low-dose radiation therapy (5 fractions of 2 Gy each)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: High-dose radiation therapy (10 fractions of 2 Gy each)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: High-dose radiation therapy (5 fractions of 3.5 Gy each)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Use of NSAID
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: High RT dose with short duration (<= 9 days)
Number of subjects: 137
Study: 3152586

Group type: EXPERIMENTAL
Intervention: Glyburide
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Glipizide
Number of subjects: 109
Study: 11403539

Group type: EXPERIMENTAL
Intervention: High-dose intravenous proton pump inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: H2-receptor antagonists
Number of subjects: 0
Study: 29792242

Group type: EXPERIMENTAL
Intervention: Unguided self-help (USH)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Group psychodynamic-interpersonal psychotherapy (GPIP)
Number of subjects: 135

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 135
Study: 30105381

Group type: EXPERIMENTAL
Intervention: LifeSkills intervention
Number of subjects: 190

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 190
Study: 26904982

Group type: EXPERIMENTAL
Intervention: Crush stenting
Number of subjects: 300

Group type: COMPARATOR
Intervention: Culotte stenting
Number of subjects: 300
Study: 25415737

Group type: EXPERIMENTAL
Intervention: Small doxorubicin drug-eluting beads (100-300 µm)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Large doxorubicin drug-eluting beads (300-500 and 500-700 µm)
Number of subjects: 94
Study: 22495030

Group type: EXPERIMENTAL
Intervention: Pterygium excision with conjunctival autograft plus corneal polishing
Number of subjects: 16
Study: 20881754

Group type: EXPERIMENTAL
Intervention: Nizatidine controlled release (CR) 150 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Nizatidine controlled release (CR) 300 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Nizatidine controlled release (CR) 300 mg in diabetic patients with DGE (n = 10)
Number of subjects: 39
Study: 17659916

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) 10 microg/kg/day for 5 days
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 41
Study: 15840681

Group type: EXPERIMENTAL
Intervention: CsA microemulsion, steroids, mycophenolate sodium and basiliximab
Number of subjects: 41
Study: 11832356

Group type: COMPARATOR
Intervention: Ibuprofen (IBU; 1,200 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Acetaminophen (ACET; 4,000 mg/day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Placebo (PLA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ibuprofen (IBU) and Acetaminophen (ACET)
Number of subjects: 24
Study: 10082173

Group type: EXPERIMENTAL
Intervention: Med‐E‐Jet
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Biojector
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 100

Group type: COMPARATOR
Intervention: Needle infiltration
Number of subjects: 100
Study: 7772487

Group type: EXPERIMENTAL
Intervention: Topical cyclosporin (CyA) 500 mg as a swish-and-spit medication for 5 min three times daily for 6 weeks
Number of subjects: 13

Group type: COMPARATOR
Intervention: Corticosteroid oral paste (triamcinolone acetonide) for 6 weeks
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: CyA therapy following corticosteroid treatment
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Follow-up for up to 1 year after treatment
Number of subjects: 13
Study: 2112184

Group type: EXPERIMENTAL
Intervention: Recombinant interferon-gamma (rIFN gamma) administered by daily 2-hour bolus injection or by continuous infusion for 14 days at dosages ranging from 3 to 3,000 micrograms/m2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant interferon-gamma (rIFN gamma)
Number of subjects: 0
Study: 100129

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: BRL10833
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31860566

Group type: EXPERIMENTAL
Intervention: Transvaginal mesh
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Sacral colpopexy
Number of subjects: 360

Group type: COMPARATOR
Intervention: Native tissue transvaginal repair
Number of subjects: 360
Study: 31403587

Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 96
Study: 27677943

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25840904

Group type: EXPERIMENTAL
Intervention: Plain language table
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Visual condition
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Narrative condition
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Adequate health literacy (REALM-SF)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Higher income
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Higher subjective numeracy skills
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Higher education
Number of subjects: 343
Study: 25125716

Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard doses of testosterone
Number of subjects: 0
Study: 21910947

Group type: EXPERIMENTAL
Intervention: Whey protein-based beverage
Number of subjects: 219

Group type: COMPARATOR
Intervention: Low-protein high-carbohydrate beverage (control)
Number of subjects: 219
Study: 19828019

Group type: EXPERIMENTAL
Intervention: Coated total knee prosthesis
Number of subjects: 120

Group type: COMPARATOR
Intervention: Uncoated total knee prosthesis
Number of subjects: 120
Study: 18182868

Group type: EXPERIMENTAL
Intervention: Smoking cessation program (2 sessions, 2 hours daily for 5 days)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 38
Study: 15899020

Group type: EXPERIMENTAL
Intervention: Scotchbond Multipurpose
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 6% ferric oxalate (Sensodyne sealant)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Acid etching and NaOCl
Number of subjects: 30

Group type: COMPARATOR
Intervention: Acid etching-sealed dentine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Scotchbond Multipurpose and Sensodyne sealant
Number of subjects: 30
Study: 15311312

Group type: EXPERIMENTAL
Intervention: SRP plus subgingival minocycline (SM)
Number of subjects: 36

Group type: COMPARATOR
Intervention: SRP plus vehicle
Number of subjects: 36
Study: 11505243

Group type: EXPERIMENTAL
Intervention: Comfort touch
Number of subjects: 45
Study: 9506749

Group type: EXPERIMENTAL
Intervention: High dose flunisolide (H FN, 2000 microg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High dose triamcinolone acetonide (H TAA, 1600 microg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low dose flunisolide (L FN, 1000 microg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low dose triamcinolone acetonide (L TAA, 800 microg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 12